Cabozantinib,Nivolumab,Ipilimumab
Exelixis,bms
['/ipi', 'ipilimumab', 'nivo', 'increase,(-increased)', 'cabozantinib', 'triplet,(-triplete)', 'nivolumab', 'ipi/']
the #oncoalerttoptweet day4 #esmo22 #eons15 tweet: cabozantinib/ipilimumab/nivolumab triplet hits dfs primary endpoint (vs ipi/nivo). rr 43% +cr 3% are modest. 3 2 % increase in g3/4 toxicity may be explanation. best, 
?? Worldwide Network of Oncology Professionals & Patient Advocates with the common goal of ending cancer, we are Oncology360 degrees ?? We are #OncoAlert ??